Skip to content
MaplePortal

President Trump Announces Deals to Cut US Obesity Drug Costs

Weight-loss medications
Zepbound and Novo Nordisk's medication are displayed in this photo

American leader President Trump has disclosed arrangements aimed at reduce the price of widely-used weight-loss medications, as pharmaceutical costs emerge as a priority in his leadership's messaging about affordability.

Major Agreements with Pharmaceutical Firms

Making remarks together with drug officials at the executive mansion, Trump announced deals with the pharmaceutical company and the drug manufacturer. Individuals are expected to pay between $245 to $350 each month for weight-loss medications including Wegovy and Zepbound.

Numerous glucagon-like peptide-1 treatments, employed against diabetes and obesity, cost over $1,000 per month without insurance or savings.

Enhanced Access to Public Healthcare Programs

The agreements will expand the company's and the manufacturer's access to the federal health program and the state-federal health plan, the government's health plans for elderly and low-income Americans.

The pharmaceutical firm also stated in a release it would avoid import duties for 36 months as a component of the arrangement with the Trump administration.

Pricing Details

An estimated 10% of federal health program enrollees will be able for increased availability to GLP-1 drugs, and will be charged just $50, according to high-ranking federal representatives.

Individuals participating in Medicaid will see a phased implementation depending on when states sign up to take part.

Government-Run Portal Introduction

The weight-loss medications will be sold at lowered prices on the direct-to-consumer government-run website, a publicly managed website scheduled to debut by January.

Via TrumpRx, Wegovy and Zepbound will begin at $350 monthly usually, and fall to $250 within 24 months. The Medicare prices of Novo Nordisk's diabetes drug, Wegovy, Eli Lilly's treatment, and Zepbound will be $245.

More Drug Alternatives

Along with the company's Wegovy, the pharmaceutical firm's obesity pill, orforglipron, will be offered for $149 for the minimum dose, Eli Lilly stated in a release. The firm's weight-loss medication will cost $299 for a beginner dosage.

These rates are contingent upon Food and Drug Administration authorization of the medications.

Coverage Challenges

GLP-1 medications are often not covered by commercial insurers. US legislation forbids Medicare from reimbursing the drugs when employed in slimming, though they often are reimbursed when prescribed for diabetes and heart conditions. Just a dozen states offer reimbursement under Medicaid for slimming reasons.

Medical Secretary's Comments

The top health official Robert F Kennedy Jr, speaking at the presidential residence, declared the arrangements were products of months of negotiations with Eli Lilly and Novo Nordisk. He described obesity "the main driver of long-term illness" in the US.

"This will be a lifesaver to them," the Health Secretary stated.

"It's not a magic solution, this is not a quick fix," he added, emphasizing the significance of eating habit modifications and regular activity.

Background of Drug Price Efforts

Since July, Trump has been pushing medication manufacturers to cut drug prices. He sent correspondence to seventeen pharmaceutical firms in the summer, allowing them a 60-day period to reply to his requests for reduced costs.

Pfizer was the primary large pharmaceutical company to reach a agreement with the administration, reducing costs for certain medicines by as much as a large percentage on the federal portal. Pfizer furthermore committed to lower treatment costs for the state-federal health plan.

AstraZeneca and the German company have also finalized arrangements with the government in recent weeks.

Written by

Michelle Dunn

A Berlin-based travel writer with a passion for uncovering hidden historical sites and sharing authentic German experiences.

MaplePortal

Type to search articles.